Abstract
The H1N1 2009 virus is pandemic in many countries. The genome of this virus contains eight segments. Among the eight segments maximum numbers of mutation occur at the segment 1 and segment 4 which codes for PB2 subunit and hemagglutinin (HA) and less number of mutations occur in segment 6 which codes for neuraminidase (NA) protein. Neuraminidase (NA) inhibitors (Oseltamivir and Zanamivir) are presently used as an anti-flu drugs. In the present study, the in silico efficacy of different drugs was tested against the swine flu virus. 3D structures of neuraminidase (NA) proteins of H1N1 2009 were generated using Geno3D. The 3D structure of H1N1 1918 was downloaded from PDB. Interaction study was done using Arguslab 4 and PyMol view. Oseltamivir and Zanamivir have good number of interactions with H1N1 2009 virus and the scoring function also support to this result. When compared with the 1918 H1N1 viral protein, 2009 H1N1 NA protein shows more number of interaction and good scoring function. The RMSD value of before and after docking are found to be same at 0.04A° for both the drugs. The force field energy of NA protein 2009 was found to be −15603.529 KJ/mol before docking. The force field energy was found to be decreased after docking at −17620.740 KJ/mol with Tamiflu and −17652.242 KJ/mol with Zanamivir. The number of interaction and scoring function shows that Oseltamivir and Zanamivir will be able to effectively control the present pandemic H1N1 virus 2009.
Keywords: H1N1, Zanamivir, Oseltamivir, Neuraminidase, Hemagglutinin
Full Text
The Full Text of this article is available as a PDF (284.2 KB).
References
- 1.Michaelis M., Doerr H., Cinatl J.J. Novel swineorigin influenza a virus in humans another pandemic knocking at the door. Med Microbiol Immunol. 2009;198(3):175–183. doi: 10.1007/s00430-009-0118-5. [DOI] [PubMed] [Google Scholar]
- 2.Zaraket H., Saito R., Sato I., Suzuki Y. Molecular evolution of human influenza a viruses in a local area during eight influenza epidemics from 2000 to 2007. Arch Virol. 2009;154(2):285–229. doi: 10.1007/s00705-009-0309-9. [DOI] [PubMed] [Google Scholar]
- 3.Kirti K., Pooja S., Rup L. Swine flu virus H1N1: a threat to human health. Indian J Microbiol. 2009;49:201. doi: 10.1007/s12088-009-0040-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Morens D., Taubenberger J., Fauci A. The Persistent Legacy of the 1918 influenza virus. N Engl J Med. 2009;361:363. doi: 10.1056/NEJMp0904819. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Kou Z., Hu S., Li T. Genome evolution of novel influenza a (H1N1) viruses in humans. Chinese Sci Bull. 2009;54:2159–2163. doi: 10.1007/s11434-009-0412-z. [DOI] [Google Scholar]
- 6.Shinde V., et al. Triple-Reassortant Swine Influenza A (H1) in Humans in the United States. 2005–2009. N Engl J Med. 2009;360:2616–2625. doi: 10.1056/NEJMoa0903812. [DOI] [PubMed] [Google Scholar]
- 7.Moscona A. Global transmission of oseltamivir-resistant influenza. N Engl J Med. 2009;360(10):953–956. doi: 10.1056/NEJMp0900648. [DOI] [PubMed] [Google Scholar]
- 8.Hayden F. Antiviral resistance in influenza viruses-implications for management and pandemic response. N Engl J Med. 2006;354(8):785–786. doi: 10.1056/NEJMp068030. [DOI] [PubMed] [Google Scholar]
- 9.Lackenby A., Hungnes O., Dudman S.G., et al. Emergence of resistance to Oseltamivir among influenza A (H1N1) virus in Europe. Eurosurveillance. 2008;13:1–3. doi: 10.2807/ese.13.05.08026-en. [DOI] [PubMed] [Google Scholar]
- 10.Mihajlovic M., Mitrasinovic P. Some novel insights into the binding of oseltamivir and zanamivir to H5N1 and N9 influenza virus neuraminidases: a homology modeling and flexible docking study. Journal of the Serbian Chemical Society. 2009;74(1):1–13. doi: 10.2298/JSC0901001M. [DOI] [Google Scholar]
- 11.Vries E., Berg B., Schutten M. Fatal Oseltamivir-resistant influenza virus infection. N Engl J Med. 2008;359(10):1074–1076. doi: 10.1056/NEJMc0803120. [DOI] [PubMed] [Google Scholar]
- 12.Moscona A. Oseltamivir Resistance — Disabling Our Influenza Defenses. N Engl J Med. 2005;353:2633–2636. doi: 10.1056/NEJMp058291. [DOI] [PubMed] [Google Scholar]